Last Price
1.82
Today's Change
+0.035 (1.95%)
Day's Change
1.76 - 1.83
Trading Volume
159,972
Market Cap
338 Million
Shares Outstanding
185 Million
Avg Volume
1,521,458
Avg Price (50 Days)
1.74
Avg Price (200 Days)
1.91
PE Ratio
-16.59
EPS
-0.11
Earnings Announcement
03-Mar-2025
Previous Close
1.79
Open
1.78
Day's Range
1.76 - 1.835
Year Range
1.38 - 2.59
Trading Volume
159,972
1 Day Change
1.96%
5 Day Change
-0.27%
1 Month Change
2.53%
3 Month Change
-10.98%
6 Month Change
4.29%
Ytd Change
-15.51%
1 Year Change
8.63%
3 Year Change
-72.05%
5 Year Change
-52.47%
10 Year Change
-60.50%
Max Change
-84.95%
No result.
Sector: Healthcare - Healthcare
Industry: Medical Devices
Description:
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.